Adam Friedman

Adam Friedman, MD, PhD, serves as the President and CEO of Scorpion Therapeutics since March 2020, also holding previous titles such as Interim Chief Executive Officer and Executive Vice President for Corporate Development & Operations. In addition, Adam Friedman co-founded Raze Therapeutics, Inc. in April 2013, where the role includes serving as President and a member of the Board of Directors, focusing on small molecule drug discovery for various diseases. Adam Friedman founded Vivid Biosciences in July 2016, leading the company in developing targeted therapeutics through advanced patient biopsy screening. Prior experience includes positions as Entrepreneur-in-Residence at Atlas Venture and a Research Fellow at Massachusetts General Hospital, alongside clinical roles at Harvard Medical School and Boston Children's Hospital. Adam Friedman holds an MD and PhD in Medicine and Genetics from Harvard Medical School, an MD in Health, Sciences, and Technology from Massachusetts Institute of Technology, and an AB in Molecular Biology from Princeton University.